Sponsors (12)
The bill increases drug-source transparency and strengthens traceability—improving patient safety and streamlining import labeling—while imposing new compliance costs, possible supply delays, and some loss of country-of-origin visibility and manufacturer confidentiality.
Patients, hospitals, pharmacies, and regulators can identify finished-drug manufacturers and API sources on labels and certificates, enabling faster recalls, better safety responses, and reduced risk of counterfeit or contaminated ingredients.
Consumers can access manufacturer and facility identifiers electronically (or on paper by request), increasing transparency about drug sourcing and allowing individuals to check product provenance.
Manufacturers, importers, and distributors benefit from harmonized FDA/customs labeling rules so a single FDA-conforming label can satisfy customs, simplifying compliance, speeding customs processing, and modestly lowering administrative and distribution costs.
Small and other drug manufacturers, importers, and distributors will face new compliance costs (systems, portals, label/CofA changes) and regulatory uncertainty if FD&C labeling evolves, which could squeeze margins or be passed on to consumers.
Some finished drug imports may no longer display explicit country-of-origin markings under the harmonized FD&C standard, reducing consumer visibility into where drugs were made.
Smaller API and finished-drug makers may need to change packaging and insert processes to meet new labeling/identifier rules, risking production slowdowns or temporary product availability delays.
Based on analysis of 3 sections of legislative text.
Requires finished drugs and APIs to identify the original manufacturer and supply‑chain facility identifiers on labels or via allowed electronic links, and aligns customs marking with FDA labeling.
Introduced February 5, 2026 by Richard Lynn Scott · Last progress February 5, 2026
Requires finished drug products and active pharmaceutical ingredients (APIs) to carry labeling that identifies the original manufacturer and supply‑chain facility identifiers, and permits links to searchable electronic portals while requiring paper information on request. It also makes the new FDA labeling standard control how finished drug products are marked for country‑of‑origin under the Tariff Act, and directs the FDA to issue implementation regulations (with an effective date at least one year after final rule publication).